ArticleHead and neck pathology2025
Salivary Epithelial-Myoepithelial Carcinoma: Clinical, Histopathological and Molecular Study from A Latin American Case Series with a Novel MSH3 Driver.
Article in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEpithelial-myoepithelial carcinoma (EMC) is a rare malignant neoplasm of the salivary glands. Although most studies have reported the predominant, recurring driver mutation is in HRAS, its molecular pathogenesis is not yet fully understood. The aim of this study is to describe the clinical and histopathological characteristics of a case series of salivary EMC with non-RAS genetic variants.
methodsFifteen formalin-fixed paraffin-embedded (FFPE) samples of EMC were retrospectively retrieved. Clinicopathological data was recovered from medical records. Two cases with sufficient tissue were assessed through next-generation sequencing (NGS).
resultsEMC occurred more frequently in females (60%). The mean age at diagnosis was 59.5 (± 14.5) years. The parotid was the most common primary site (80%). Time from first symptoms to diagnosis was 41 months in average. Pathological staging I, II and III occurred in 21.4%, 28.6% and 50% of the cases, respectively. Only one participant had regional lymph node involvement, and none were metastatic. The margins were involved in 41.6% of cases. All the patients were surgically treated, including neck dissection in two subjects, and 33% received adjuvant radiotherapy. One patient relapsed (6.7%) after an average of 32.4 months of follow-up. NGS analysis revealed 160 germline mutations in 46 genes of interest, of which 11 were previously described as pathogenic or as variant of uncertain significance (VUS). Only one somatic frameshift deletion involving MSH3 (c.1148del p.K383Rfs*32) gene was detected.
conclusionThis study explores EMC in a Latin American cohort. The findings align with global literature, and a novel MSH3 mutation was identified. However, further research is needed to confirm its significance and potential impact on tumor behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.